Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

Abstract: An isolated polynucleotide includes: (a) a polynucleotide sequence as shown in SEQ ID NO: 1; or (b) a polynucleotide sequence comprising at least 15 or 17 or 19 or 21 contiguous nucleotides of SEQ ID NO: 1, wherein the ingestion, by Coleoptera insect pests, of a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence inhibits the growth of the Coleoptera insect pests; or (c) any one of the polynucleotide sequence as shown in SEQ ID NO: 3 to SEQ ID NO: 6; or (d) a polynucleotide sequence hybridized with the polynucleotide sequence defined in (a), (b) or (c) mentioned above under stringent conditions. Multiple target sequences of the target gene c46312 control the Coleoptera insect pest Monolepta hieroglyphica.

Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: An isolated polynucleotide includes: (a) a polynucleotide sequence as shown in SEQ ID NO: 1; or (b) a polynucleotide sequence having at least 15, 17, 19 or 21 contiguous nucleotides of SEQ ID NO: 1, wherein the growth of a pest of the order Coleoptera is inhibited when the pest of the order Coleoptera ingests double-stranded RNA comprising at least one strand that is complementary to the described polynucleotide sequence; or (c) any polynucleotide sequence as shown in SEQ ID NO: 3 to SEQ ID NO: 6; or (d) a polynucleotide sequence which hybridizes under stringent conditions with the polynucleotide sequence as defined in (a), (b) or (c). A plurality of target sequences are used for controlling a target gene c4506 of Monolepta hieroglyphica, which is a pest of the order Coleoptera.

Abstract: Provided are an isolated polynucleotide and a method for controlling insect invasion. The isolated polynucleotide is a plurality of target sequences for controlling target gene c35112 of a coleopteran pest, Monolepta hieroglyphica, comprising: a) a polynucleotide sequence shown as SEQ ID NO: 1; or (b) a polynucleotide sequence having at least 15 or 17 or 19 or 21 contiguous nucleotides of SEQ ID NO: 1, a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence being capable of inhibiting the growth of coleopteran pests after being ingested by the coleopteran pests; or (c) any one of polynucleotide sequences shown as SEQ ID NO: 3 to SEQ ID NO: 20; or (d) a polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence as defined in (a), (b) or (c).

Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse/addiction and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: Provided are a resistant protein for use in herbicide dicamba, encoding gene and application thereof, the gene comprising: (a) a nucleotide sequence of an amino acid sequence as shown in SEQ ID NO: 2; or (b) a nucleotide sequence which is complementary to the nucleotide sequence as defined by (a) under stringent conditions; or (c) a nucleotide sequence as shown in SEQ ID NO: 1.

Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.

Abstract: An isolated polynucleotide includes: (a) a polynucleotide sequence as shown in SEQ ID NO: 1; or (b) a polynucleotide sequence comprising at least 15 or 17 or 19 or 21 contiguous nucleotides of SEQ ID NO: 1, wherein the ingestion, by Coleoptera insect pests, of a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence inhibits the growth of the Coleoptera insect pests; or (c) any one of the polynucleotide sequence as shown in SEQ ID NO: 3 to SEQ ID NO: 6; or (d) a polynucleotide sequence hybridized with the polynucleotide sequence defined in (a), (b) or (c) mentioned above under stringent conditions. Multiple target sequences of the target gene c46312 control the Coleoptera insect pest Monolepta hieroglyphica.

Abstract: An isolated polynucleotide includes: (a) a polynucleotide sequence as shown in SEQ ID NO: 1; or (b) a polynucleotide sequence having at least 15, 17, 19 or 21 contiguous nucleotides of SEQ ID NO: 1, wherein the growth of a pest of the order Coleoptera is inhibited when the pest of the order Coleoptera ingests double-stranded RNA comprising at least one strand that is complementary to the described polynucleotide sequence; or (c) any polynucleotide sequence as shown in SEQ ID NO: 3 to SEQ ID NO: 6; or (d) a polynucleotide sequence which hybridizes under stringent conditions with the polynucleotide sequence as defined in (a), (b) or (c). A plurality of target sequences are used for controlling a target gene c4506 of Monolepta hieroglyphica, which is a pest of the order Coleoptera.

Abstract: Provided are an isolated polynucleotide and a method for controlling insect invasion. The isolated polynucleotide is a plurality of target sequences for controlling target gene c35112 of a coleopteran pest, Monolepta hieroglyphica, comprising: a) a polynucleotide sequence shown as SEQ ID NO: 1; or (b) a polynucleotide sequence having at least 15 or 17 or 19 or 21 contiguous nucleotides of SEQ ID NO: 1, a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence being capable of inhibiting the growth of coleopteran pests after being ingested by the coleopteran pests; or (c) any one of polynucleotide sequences shown as SEQ ID NO: 3 to SEQ ID NO: 20; or (d) a polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence as defined in (a), (b) or (c).

Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: Disclosed are a nucleotide sequence and a method for controlling insect invasions, the isolated polynucleotide sequence comprising: (a) a polynucleotide sequence as shown in SEQ ID NO: 1, 2 or 3; or (b) a polynucleotide sequence hybridizing with the polynucleotide sequence defined in (a) under stringent conditions; or (c) a polynucleotide sequence having an identity of not less than 80% to the polynucleotide sequence defined in (a); or (d) a polynucleotide sequence of at least 19 consecutive nucleotides of the polynucleotide sequence defined in (a), wherein a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence, when ingested by an insect pest from Hemiptera, inhibits growth of the insect pest; or (e) a complementary sequence of the polynucleotide sequence as defined in (a), (b), (c) or (d). The three target sequences for controlling an insect pest from Hemiptera, Lygus, have the advantages of efficiency, specificity, convenience and low cost.

Abstract: The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.

Abstract: Involved is a herbicide-resistant protein, coding gene and use thereof. The herbicide-resistant protein comprises: (a) a protein consisting of an amino acid sequence shown in SEQ ID NO: 2; or (b) a protein with the activity of herbicide-resistance which is derived from the amino acid sequence in (a) by replacing and/or deleting and/or adding one or several amino acids in the same. The herbicide-resistant protein of this invention is especially suitable for expression in plants, with broad resistance spectrum to herbicides, especially to phenoxy auxin herbicides.

Abstract: Disclosed are a nucleotide sequence and a method for controlling insect invasions, the isolated polynucleotide sequence comprising: (a) a polynucleotide sequence as shown in SEQ ID NO: 1, 2 or 3; or (b) a polynucleotide sequence hybridizing with the polynucleotide sequence defined in (a) under stringent conditions; or (c) a polynucleotide sequence having an identity of not less than 80% to the polynucleotide sequence defined in (a); or (d) a polynucleotide sequence of at least 19 consecutive nucleotides of the polynucleotide sequence defined in (a), wherein a double-stranded RNA comprising at least one strand complementary to the polynucleotide sequence, when ingested by an insect pest from Hemiptera, inhibits growth of the insect pest; or (e) a complementary sequence of the polynucleotide sequence as defined in (a), (b), (c) or (d). The three target sequences for controlling an insect pest from Hemiptera, Lygus, have the advantages of efficiency, specificity, convenience and low cost.

Abstract: Provided are a resistant protein for use in herbicide dicamba, encoding gene and application thereof, the gene comprising: (a) a nucleotide sequence of an amino acid sequence as shown in SEQ ID NO: 2; or (b) a nucleotide sequence which is complementary to the nucleotide sequence as defined by (a) under stringent conditions; or (c) a nucleotide sequence as shown in SEQ ID NO: 1.

Abstract: Clostridium difficile infection (CDI) is a public health threat that results in 14,000 annual deaths in the United States. Challenges involve the production of CDI spores that can remain dormant for years and the production of toxins that damage the gut. Current therapies for CDI include vancomycin and metronidazole, but neither inhibits spore or toxin production. Thus, recurrence of infection occurs in 25% of patients and there are no antibiotics that are effective for multiple recurrences. We describe oxadiazoles with activity against C. difficile, including the highly virulent NAP1/027 strain with increased production of toxins A and B, as well as the additional binary toxin. Oxadiazole 2 is poorly absorbed, thus advantageously achieving high concentrations in the gut. The compound targets peptidoglycan synthesis and inhibits vegetative cells, spores, and toxin production.